Medicine information ZEQUIPRA 2.5mg film-coated tablets

Product code:
W62173002
Quantity:
30
Indicated for:
breast cancer
Route of administration:
oral
Substance:
letrozole (aromatase inhibitor)
ATC
L02BG04 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors
Letrozole is a hormonal medicine used to treat certain types of breast cancer that depend on oestrogen, particularly in women who have gone through menopause. It blocks the aromatase enzyme and reduces the body's production of oestrogens. Lower hormone levels can slow or stop the growth of tumour cells that are sensitive to oestrogen.

It is taken by mouth, usually once a day, exactly as directed by the oncology team. Treatment may continue for several years depending on the type and stage of the disease and the patient's response. Do not stop taking it or change the dose without medical advice. Regular appointments are needed to assess treatment benefit and side effects.

Common side effects include hot flushes, sweating, joint or bone pain, tiredness, headache and nausea. By lowering oestrogen levels, letrozole can reduce bone mineral density and increase the risk of osteoporosis and fractures. Cholesterol may also rise in some patients. The doctor may recommend bone-density assessment and blood-test monitoring.

Tell the doctor about persistent bone pain, fractures, chest pain, shortness of breath, leg swelling or allergic reactions. Letrozole must not be used during pregnancy or breastfeeding and is generally not intended for women who have not reached menopause, except in specialist treatment regimens. Inform the oncology team about liver or kidney disease and all medicines you take.

General data about ZEQUIPRA 2.5mg

Substance:
letrozole
Date of latest medicines list:
01-11-2026
Product code:
W62173002
Strength:
2.5mg
Pharmaceutical form:
film-coated tablets
Quantity:
30
Product type:
Generic medicine
Price:
83.78 RON
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
WEST PHARMA PRODUCOES DE ESPECIALIDADES FARM. S.A. - PORTUGALIA
Holder:
NEOLA PHARMA S.R.L. - ROMANIA
Number:
6664/2014/02
Shelf life:
4 years

Pharmaceutical forms available for letrozole

Official documents

The correspondence between the document and the displayed text is unconfirmed.

Source institution
ANMDMR
Document language
Romanian

Reimbursement lists for ZEQUIPRA 2.5mg Neola Pharma

NHP 3 (C2) - NHP oncology

Price
83.78 RON
Copayment
83.78 RON
Patient payment
0.00 RON